Highlights in lung cancer in 2019.
File(s)Highlights in lung cancer in 2019.pdf (157.45 KB)
Published version
Author(s)
Lim, Kok Haw Jonathan
Popat, Sanjay
Type
Journal Article
Abstract
There have been significant advances in the treatment landscape of lung cancer in the recent few years. In this podcast, Jonathan Lim (a member of the European Society for Medical Oncology Young Oncologists Committee) interviews Professor Sanjay Popat (Professor of Thoracic Medical Oncology at The Royal Marsden Hospital, UK) on the highlights of lung cancer in 2019.
Professor Popat provides his perspective and contextualises how some of the key studies reported this year (including CheckMate 227, IMpower110, KEYNOTE 042, FLAURA and CASPIAN) have been practice-changing. We also discuss the current utility and caveats of PD-L1(programmed death-ligand 1) as a biomarker for immunotherapy with anti-PD1, and explore progress made in the clinical translation of circulating tumour DNA, circulating tumour cell and tumour mutational burden. Finally, we talk about the recent hype on targeting KRAS in non-small cell lung cancer, and highlight what is on the horizon in 2020. Click here to listen to the Podcast (https://soundcloud.com/bmjpodcasts/highlights-in-lung-cancer-2019?in=bmjpodcasts/sets/esmo-open).
Professor Popat provides his perspective and contextualises how some of the key studies reported this year (including CheckMate 227, IMpower110, KEYNOTE 042, FLAURA and CASPIAN) have been practice-changing. We also discuss the current utility and caveats of PD-L1(programmed death-ligand 1) as a biomarker for immunotherapy with anti-PD1, and explore progress made in the clinical translation of circulating tumour DNA, circulating tumour cell and tumour mutational burden. Finally, we talk about the recent hype on targeting KRAS in non-small cell lung cancer, and highlight what is on the horizon in 2020. Click here to listen to the Podcast (https://soundcloud.com/bmjpodcasts/highlights-in-lung-cancer-2019?in=bmjpodcasts/sets/esmo-open).
Date Issued
2020-02
Date Acceptance
2020-02-01
Citation
ESMO Open, 2020, 5 (1), pp.1-1
ISSN
2059-7029
Publisher
BMJ Publishing Group
Start Page
1
End Page
1
Journal / Book Title
ESMO Open
Volume
5
Issue
1
Copyright Statement
© Author (s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ on behalf of the European Society for Medical Oncology. http://creativecommons.org/licenses/by-nc/4.0/
This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, any changes made are indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, any changes made are indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
Identifier
https://www.ncbi.nlm.nih.gov/pubmed/32054634
PII: esmoopen-2020-000676
Subjects
Podcast
Publication Status
Published
Coverage Spatial
England
Date Publish Online
2020-02-13